2. Search Result
Search Result
Results for "

Cetuximab

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

3

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9905
    Cetuximab
    30+ Cited Publications

    C225

    		 Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
    Cetuximab
  • HY-107460
    LDN-211904 oxalate

    		Ephrin Receptor Cancer
    LDN-211904 oxalate (compound 32) is a potent and selective EphB3 inhibitor with an IC50 of 0.079 µM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC .
    LDN-211904 oxalate
  • HY-152848
    Fulzerasib

    IBI351; GFH925

    		 Ras Cancer
    Fulzerasib (GFH925) is an irreversible KRAS G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905). .
    Fulzerasib
  • HY-P99275
    Patritumab
    1 Publications Verification

    Human Anti-ERBB3 Recombinant Antibody

    		 EGFR Akt ERK PARP Survivin Cancer
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
    Patritumab
  • HY-P99902
    Simlukafusp alfa

    FAP-IL2v

    		 Interleukin Related Cancer
    Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .
    Simlukafusp alfa
  • HY-163675
    Maleimide-PEG8-Val-Ala-PAB

    		ADC Linker Cancer
    Maleimide-PEG8-Val-Ala-PAB is an ADC linker composed of the cleavable Val-Ala-PAB (HY-125933) linker and the probe molecule Maleimide (HY-W007324). Maleimide-PEG8-Val-Ala-PAB can be used to connect Cetuximab (HY-P9905) monoclonal antibody and CDK inhibitor SNS-032 (HY-10008) to synthesize antibody-drug conjugates (ADCs) .
    Maleimide-PEG8-Val-Ala-PAB
  • HY-164492
    LSN3074753

    		Raf Cancer
    LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or RAF dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation .
    LSN3074753

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: